- Hologic Inc (NASDAQ:HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion.
- Lower sales of COVID-19 assays primarily drove a fall in sales.
- Hologic's global diagnostics business posted revenues of $987.1 million, down 7%.
- Diagnostics revenues excluding COVID-19 revenues were $290.4 million, up 3%.
- Hologic said its COVID-19 revenues were down 14% and included assay revenues of $584.1 million.
- Hologic reported adjusted EPS of $2.07 and beat analysts' average estimate of $1.60 per share.
- The company ended the quarter with $2.29 billion in cash and cash equivalents.
- Guidance: For Q3, Hologic anticipates revenues of $875 - $915 million and adjusted EPS of $0.67 to $0.72, compared to the consensus of $893.51 million and $0.70, respectively.
- For FY22, the company expects revenues of $4.6 billion - $4.7 billion compared to previous guidance of $4.4 billion - $4.55 billion and a consensus of $4.53 billion.
- Hologic forecasts adjusted EPS of $5.45 - $5.65 compared to previous guidance of $4.90 to $5.20 and the consensus of $5.15.
- Price Action: HOLX shares are up 1.24% at $71.72 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks